TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma

Shrestha,Ritu; Bridle,Kim  R.; Crawford,Darrell  H.G.; Jayachandran,Aparna

doi:10.3892/mmr.2020.10991

TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma

Authors:
- Ritu Shrestha
- Kim R. Bridle
- Darrell H.G. Crawford
- Aparna Jayachandran
View Affiliations

Affiliations: University of Queensland, Faculty of Medicine, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia
Published online on: February 19, 2020 https://doi.org/10.3892/mmr.2020.10991
Pages: 1849-1860
Copyright: © Shrestha et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer‑related deaths globally. Epithelial‑to‑mesenchymal transition (EMT) is a cellular process that confers HCC tumor cells with the ability to evade the immune system. Immune escape in most tumors, including HCC, is controlled by immune checkpoint molecules. The aim of the present study was to investigate the association between EMT and immune checkpoint in HCC, and identify novel therapeutic targets for HCC. An in vitro model of reversible EMT was utilized based on cytokine tumor necrosis factor (TNF)‑α treatment of HCC cell lines Hep3B and PLC/PRF/5. Hep3B and PLC/PRF/5 cells were treated with TNF‑α, and the EMT status and the expression of immune checkpoint molecules was assessed by reverse transcription‑quantitative PCR, western blotting and immunofluorescence. To confirm an association between EMT and immune modulators, cells were exposed to culture medium with TNF‑α for 3 days to induce EMT, following which a reversal assay was performed. The expression of immune modulators and mesenchymal‑to‑epithelial transition (MET) status was investigated upon reversal of EMT. Furthermore, SurvExpress, a web‑based platform was utilized to analyze survival and recurrence in a dataset of patients with HCC. TNF‑α treatment for 3 days induced EMT in Hep3B and PLC/PRF/5 cells, as demonstrated by the downregulation of epithelial markers along with upregulation in mesenchymal markers. An EMT reversal assay was able to induce MET by increasing epithelial markers and decreasing mesenchymal markers. TNF‑α‑induced EMT led to the upregulation of immune modulators, including programmed death receptor ligand (PD‑L)1, PD‑L2, CD73 and B7‑H3. In contrast, reversal of EMT suppressed the expression of PD‑L1, PD‑L2, CD73 and B7‑H3. In addition, high expression of TNF‑α and PD‑L1 in 422 patients with HCC was associated with poor overall survival. The coordinate expression of TNF‑α with PD‑L2 in this patient cohort was associated with increased HCC recurrence. In conclusion, the present study demonstrated a close association between immune modulator expression and EMT induction/reversal driven by TNF‑α.

View Figures

View References

1	Chacko S and Samanta S: ‘Hepatocellular carcinoma: A life-threatening disease’. Biomed Pharmacother. 84:1679–1688. 2016. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Sayiner M, Golabi P and Younossi ZM: Disease burden of hepatocellular carcinoma: A global perspective. Dig Dis Sci. 64:910–917. 2019. View Article : Google Scholar : PubMed/NCBI
4	Kudo M: A new era of systemic therapy for hepatocellular carcinoma with regorafenib and lenvatinib. Liver Cancer. 6:177–184. 2017. View Article : Google Scholar : PubMed/NCBI
5	Mir N, Jayachandran A, Dhungel B, Shrestha R and Steel JC: Epithelial-to-mesenchymal transition: A Mediator of sorafenib resistance in advanced hepatocellular carcinoma. Curr Cancer Drug Targets. 17:698–706. 2017. View Article : Google Scholar : PubMed/NCBI
6	Sharma P and Allison JP: The future of immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
7	Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI
8	Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DH, Dhungel B, Steel JC and Jayachandran A: Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front Oncol. 8:2692018. View Article : Google Scholar : PubMed/NCBI
9	Hato T, Goyal L, Greten TF, Duda DG and Zhu AX: Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology. 60:1776–1782. 2014. View Article : Google Scholar : PubMed/NCBI
10	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
11	Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
12	Jindal A, Thadi A and Shailubhai K: Hepatocellular carcinoma: Etiology and current and future drugs. J Clin Exp Hepatol. 9:221–232. 2019. View Article : Google Scholar : PubMed/NCBI
13	Kudo M: Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials. Oncology. 92 (Suppl 1):50–62. 2017. View Article : Google Scholar : PubMed/NCBI
14	Li Z, Li N, Li F, Zhou Z, Sang J, Chen Y, Han Q, Lv Y and Liu Z: Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine (Baltimore). 95:e57492016. View Article : Google Scholar : PubMed/NCBI
15	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
16	Jayachandran A, Dhungel B and Steel JC: Epithelial-to-mesenchymal plasticity of cancer stem cells: Therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 9:742016. View Article : Google Scholar : PubMed/NCBI
17	David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J and Palena C: A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. OncoImmunology. 6:e13495892017. View Article : Google Scholar : PubMed/NCBI
18	David JM, Dominguez C and Palena C: Pharmacological and immunological targeting of tumor mesenchymalization. Pharmacol Ther. 170:212–225. 2017. View Article : Google Scholar : PubMed/NCBI
19	Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M and Ghebeh H: Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. Mol Cancer. 14:1492015. View Article : Google Scholar : PubMed/NCBI
20	Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, Tan TZ, Mami-Chouaib F, Thiery JP and Chouaib S: The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology. 6:e12634122017. View Article : Google Scholar : PubMed/NCBI
21	Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, et al: PD-L1 expression is regulated by both DNA methylation and NF-κB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 7:e14231702018. View Article : Google Scholar : PubMed/NCBI
22	Imai D, Yoshizumi T, Okano S, Itoh S, Ikegami T, Harada N, Aishima S, Oda Y and Maehara Y: IFN-γ promotes epithelial-mesenchymal transition and the expression of PD-L1 in pancreatic cancer. J Surg Res. 240:115–123. 2019. View Article : Google Scholar : PubMed/NCBI
23	Chen L, Xiong Y, Li J, Zheng X, Zhou Q, Turner A, Wu C, Lu B and Jiang J: PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell Physiol Biochem. 42:2267–2280. 2017. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Hu J, Wang Y, Ye W, Zhang X, Ju H, Xu D, Liu L, Ye D, Zhang L, et al: EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. Cell Cycle. 17:1457–1470. 2018. View Article : Google Scholar : PubMed/NCBI
25	Chen Y, Wen H, Zhou C, Su Q, Lin Y, Xie Y, Huang Y, Qiu Q, Lin J, Huang X, et al: TNF-α derived from M2 tumor-associated macrophages promotes epithelial-mesenchymal transition and cancer stemness through the Wnt/β-catenin pathway in SMMC-7721 hepatocellular carcinoma cells. Exp Cell Res. 378:41–50. 2019. View Article : Google Scholar : PubMed/NCBI
26	Jayachandran A, Shrestha R, Dhungel B, Huang IT, Vasconcelos MY, Morrison BJ, Ramlogan-Steel CA and Steel JC: Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity. World J Stem Cells. 9:159–168. 2017. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress: An online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 8:e742502013. View Article : Google Scholar : PubMed/NCBI
29	Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, et al: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69:7385–7392. 2009. View Article : Google Scholar : PubMed/NCBI
30	Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI
31	Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H and Rusyn I: Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer. 9:742010. View Article : Google Scholar : PubMed/NCBI
32	Awan FM, Naz A, Obaid A, Ali A, Ahmad J, Anjum S and Janjua HA: Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach. PLoS One. 10:e01389132015. View Article : Google Scholar : PubMed/NCBI
33	Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 12:5369–5376. 2006. View Article : Google Scholar : PubMed/NCBI
34	Xu Z, Shen MX, Ma DZ, Wang LY and Zha XL: TGF-beta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. Cell Res. 13:343–350. 2003. View Article : Google Scholar : PubMed/NCBI
35	Zhu Y, Cheng Y, Guo Y, Chen J, Chen F, Luo R and Li A: Protein kinase D2 contributes to TNF-α-induced epithelial mesenchymal transition and invasion via the PI3K/GSK-3β/β-catenin pathway in hepatocellular carcinoma. Oncotarget. 7:5327–5341. 2016.PubMed/NCBI
36	Xu F, Jin T, Zhu Y and Dai C: Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 37:1102018. View Article : Google Scholar : PubMed/NCBI
37	Afreen S and Dermime S: The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematol Oncol Stem Cell Ther. 7:1–17. 2014. View Article : Google Scholar : PubMed/NCBI
38	Mu CY, Huang JA, Chen Y, Chen C and Zhang XG: High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 28:682–688. 2011. View Article : Google Scholar : PubMed/NCBI
39	Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, et al: Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 146:15–24. 2014. View Article : Google Scholar : PubMed/NCBI
40	Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, Yang AG and Wen WH: B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 8:e760122013. View Article : Google Scholar : PubMed/NCBI
41	Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, et al: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
42	Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, et al: Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features. Hepatology. 64:2038–2046. 2016. View Article : Google Scholar : PubMed/NCBI
43	Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO and Parsa AT: PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 28:306–312. 2009. View Article : Google Scholar : PubMed/NCBI
44	Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD and Durden DL: The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 68:1862–1871. 2008. View Article : Google Scholar : PubMed/NCBI
45	Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T and Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 121:751–758. 2007. View Article : Google Scholar : PubMed/NCBI
46	Funaki S, Shintani Y, Kawamura T, Kanzaki R, Minami M and Okumura M: Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer. Oncol Rep. 38:2277–2284. 2017. View Article : Google Scholar : PubMed/NCBI
47	Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2:261–268. 2001. View Article : Google Scholar : PubMed/NCBI
48	Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS and Baek MJ: Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 49:246–254. 2017. View Article : Google Scholar : PubMed/NCBI
49	Yang H, Zhou X, Sun L and Mao Y: Correlation Between PD-L2 expression and clinical outcome in solid cancer patients: A meta-analysis. Front Oncol. 9:472019. View Article : Google Scholar : PubMed/NCBI
50	Ma XL, Shen MN, Hu B, Wang BL, Yang WJ, Lv LH, Wang H, Zhou Y, Jin AL, Sun YF, et al: CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol. 12:372019. View Article : Google Scholar : PubMed/NCBI
51	Sciarra A, Monteiro I, Ménétrier-Caux C, Caux C, Gilbert B, Halkic N, La Rosa S, Romero P, Sempoux C and de Leval L: CD73 expression in normal and pathological human hepatobiliopancreatic tissues. Cancer Immunol Immunother. 68:467–478. 2019. View Article : Google Scholar : PubMed/NCBI
52	Qiao Z, Li X, Kang N, Yang Y, Chen C, Wu T, Zhao M, Liu Y and Ji X: A Novel specific Anti-CD73 antibody inhibits triple-negative breast cancer cell motility by regulating autophagy. Int J Mol Sci. 20:E10572019. View Article : Google Scholar : PubMed/NCBI
53	Dong P, Xiong Y, Yue J, Hanley SJB and Watari H: B7H3 as a promoter of metastasis and promising therapeutic target. Front Oncol. 8:2642018. View Article : Google Scholar : PubMed/NCBI
54	Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG and Sun DX: B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 15:452015. View Article : Google Scholar : PubMed/NCBI
55	Zheng Y, Liao N, Wu Y, Gao J, Li Z, Liu W, Wang Y, Li M, Li X, Chen L, et al: High expression of B7 H2 or B7 H3 is associated with poor prognosis in hepatocellular carcinoma. Mol Med Rep. 19:4315–4325. 2019.PubMed/NCBI
56	Xu ZL, Zhang Y, Wang L, Li F, Man HW, Li PF and Shan BE: B7 H3 promotes malignant progression of muscle invasive bladder cancer. Oncol Rep. 40:2722–2733. 2018.PubMed/NCBI
57	Jiang B, Zhang T, Liu F, Sun Z, Shi H, Hua D and Yang C: The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer. Oncotarget. 7:31755–31771. 2016.PubMed/NCBI